Bechr Hamrita1, Hela Ben Nasr1, Philippe Hammann2, Lauriane Kuhn2, Christelle-Lemaitre Guillier3, Anouar Chaieb4, Hedi Khairi4, Karim Chahed5. 1. Laboratoire d'Immuno-Oncologie Moléculaire, Faculté de Médecine de Monastir, Tunisia. 2. Plate Forme Protéomique, Institut de Biologie Moléculaire et Cellulaire, CNRS, 67084 Strasbourg, France. 3. UMR INRA/CNRS/Université de Bourgogne, Plante Microbe Environnement (PME), France. 4. Laboratoire d'Immuno-Oncologie Moléculaire, Faculté de Médecine de Monastir, Tunisia; Service d'Obstétrique et des maladies féminines, Centre Hospitalo-Universitaire-Farhat-Hached, Sousse, Tunisia. 5. Laboratoire d'Immuno-Oncologie Moléculaire, Faculté de Médecine de Monastir, Tunisia; Faculty of Sciences, Sfax, Tunisia. Electronic address: k.chahed@yahoo.fr.
Abstract
OBJECTIVES: In the current study, we have used an immunoproteomics approach to identify proteins that commonly elicit a humoral response in patients with infiltrating ductal carcinomas of the breast. DESIGN AND METHODS: Sera obtained at the time of diagnosis from 40 patients with invasive breast cancer and 42 healthy controls were screened for the presence of IgG antibodies to MCF-7 cell line proteins using a serological proteomics-based approach. RESULTS: An immunoreactive protein detected in sera from 21 of 40 patients was isolated and subsequently identified as elongation factor-Tu. CONCLUSIONS: The immunoproteomic approach implemented here offers a powerful tool for determining novel tumor antigens that induce a humoral immune response in cancer patients. From our findings, the immunoreactive EF-Tu protein and/or the related circulating antibodies may display clinical usefulness as potential diagnostic markers and provide a means for a better understanding of the molecular mechanisms underlying breast cancer development.
OBJECTIVES: In the current study, we have used an immunoproteomics approach to identify proteins that commonly elicit a humoral response in patients with infiltrating ductal carcinomas of the breast. DESIGN AND METHODS: Sera obtained at the time of diagnosis from 40 patients with invasive breast cancer and 42 healthy controls were screened for the presence of IgG antibodies to MCF-7 cell line proteins using a serological proteomics-based approach. RESULTS: An immunoreactive protein detected in sera from 21 of 40 patients was isolated and subsequently identified as elongation factor-Tu. CONCLUSIONS: The immunoproteomic approach implemented here offers a powerful tool for determining novel tumor antigens that induce a humoral immune response in cancerpatients. From our findings, the immunoreactive EF-Tu protein and/or the related circulating antibodies may display clinical usefulness as potential diagnostic markers and provide a means for a better understanding of the molecular mechanisms underlying breast cancer development.
Authors: Wenming Zhang; Mingfeng Xiang; Chuqian Zheng; Leifeng Chen; Jin Ge; Chen Yan; Xiuxia Liu Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2018-09-30